Pharmaceutical Contract Manufacturing Market Overview
The use of medicines and treatments for well-being has expanded dramatically during the last several decades. With a limited number of blockbuster pharmaceuticals and increasing demand for innovative drugs, prominent pharmaceutical companies are attempting to stay competitive by completing drug development faster and at a lower cost. Furthermore, after the drug has received regulatory approval, these corporations have a shorter time to get the drug to market in large quantities. As a result of these issues, pharmaceutical contract manufacturers are increasingly outsourcing manufacturing facilities.
Furthermore, the global pharmaceutical contract manufacturing market is being bolstered by an infusion of tiny and virtual firms with limited manufacturing capacity. The increasing number of FDA-approved production facilities in developing nations is also helping to drive market expansion.
On the other hand, contract manufacturing companies' profitability is being harmed by capacity utilization challenges and a lack of manufacturing standardization. As a result, the market's overall revenue creation is hampered. In addition, rising logistics costs and lead times are causing distrust among pharmaceutical businesses, preventing the global pharmaceutical contract manufacturing market from reaching its full potential. The growing need for next-generation biological therapies, on the other hand, is providing producers with new opportunities in the global market.
| Report Metric | Details |
| Market size available for years | 2023–2030 |
| Base year considered | 2023 |
| Forecast period | 2024–2030 |
| Forecast unit | Value (USD Million) |
| Segments covered | Service, Technology, and Region |
| Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered | Althea Technologies, Aenova, Dishman Pharmaceuticals and Chemicals Limited, Catalent Pharma Solutions, HAUPT Pharma AG, Famar, Kemwell Pvt. Ltd., Jubilant Life Sciences Limited, Nipro Corp., NextPharma, Recipharm, Pfizer Central Source, Royal DSM N.V. |
Covid-19 Impact on Pharmaceutical Contract Manufacturing Market
In addition, the current Pharmaceutical Contract Manufacturing Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Pharmaceutical Contract Manufacturing Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Pharmaceutical Contract Manufacturing Market Segment Overview
According to Service, Packaging is one of the most important segments in the global Pharmaceutical Contract Manufacturing market. The load or size of pharmaceuticals exported and imported through manufacturing and selling organizations is dealt with by packaging. Drug Dose Formulation refers to the injectable, liquid, and solid forms of pharmaceuticals that are made available to patients. APIs are small and large molecules that vary in size based on the severity of the ailment for which the medications are prescribed. Furthermore, by technology, this market is divided into low-tech and high-tech manufactures. It deals with the process knowledge by manufacturers to deal with specific drugs.
Pharmaceutical Contract Manufacturing Market, By Service
· Packaging
· Drug Dose Formulation
· Active Pharmaceutical Ingredient (API)
Pharmaceutical Contract Manufacturing Market, By Technology
· Low-Tech Manufactures
· High-Tech Manufactures
Pharmaceutical Contract Manufacturing Market Regional Overview
Geographically, North America and Europe are important regions in the global pharmaceutical contract manufacturing market. The expanding geriatric population and strong adoption of biologics contribute to the growth of these regions. Biotechnology companies' increased research activities, as well as the expanding need for generics, are both contributing to the areas' growth. In the North American market, the United States will be a big income source. Due to growing healthcare infrastructure and increasing favorable government efforts, the Asia Pacific region is expected to emerge as a lucrative market throughout the forecast period.
Pharmaceutical Contract Manufacturing Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Pharmaceutical Contract Manufacturing Market, Key Players
· Althea Technologies
· Aenova
· Dishman Pharmaceuticals and Chemicals Limited
· Catalent Pharma Solutions
· HAUPT Pharma AG
· Famar
· Kemwell Pvt. Ltd.
· Jubilant Life Sciences Limited
· Nipro Corp.
· NextPharma
· Recipharm
· Pfizer Central Source
· Royal DSM N.V.
Frequently Asked Questions (FAQ) :
Q1. What are the driving factors for the Pharmaceutical Contract Manufacturing market?
The global pharmaceutical contract manufacturing market is being bolstered by an infusion of tiny and virtual firms with limited manufacturing capacity.
Q2. Which Segments are covered in the Pharmaceutical Contract Manufacturing Market report?
Service, Technology, and Region these segments are covered in the Pharmaceutical Contract Manufacturing market report.
Q3. Which segment is projected to hold the largest share in the Pharmaceutical Contract Manufacturing Market. ?
The packaging segment is projected to hold the largest share in the Pharmaceutical Contract Manufacturing Market.
Q4. Which region holds the largest share in the Pharmaceutical Contract Manufacturing market?
North America and Europe held the largest share in the global Pharmaceutical Contract Manufacturing market.
Q5. Which are the prominent players in the Pharmaceutical Contract Manufacturing Market?
Althea Technologies, Aenova, Dishman Pharmaceuticals and Chemicals Limited, Catalent Pharma Solutions, HAUPT Pharma AG, Famar, Kemwell Pvt. Ltd., Jubilant Life Sciences Limited, Nipro Corp., NextPharma, Recipharm, Pfizer Central Source, Royal DSM N.V. are some key players in the Pharmaceutical Contract Manufacturing Market.
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Pharmaceutical Contract Manufacturing Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Service
- 5.2.1. Packaging
- 5.2.2. Drug Dose Formulation
- 5.2.3. Active Pharmaceutical Ingredient (API)
- 5.3. Market Analysis, Insights and Forecast – By Technology
- 5.3.1. Low-Tech Manufactures
- 5.3.2. High-Tech Manufactures
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America, Middle East and Africa
6. North America Pharmaceutical Contract Manufacturing Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Service
- 6.2.1. Packaging
- 6.2.2. Drug Dose Formulation
- 6.2.3. Active Pharmaceutical Ingredient (API)
- 6.3. Market Analysis, Insights and Forecast – By Technology
- 6.3.1. Low-Tech Manufactures
- 6.3.2. High-Tech Manufactures
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Pharmaceutical Contract Manufacturing Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Service
- 7.2.1. Packaging
- 7.2.2. Drug Dose Formulation
- 7.2.3. Active Pharmaceutical Ingredient (API)
- 7.3. Market Analysis, Insights and Forecast – By Technology
- 7.3.1. Low-Tech Manufactures
- 7.3.2. High-Tech Manufactures
- 7.4. Market Analysis, Insights and Forecast – By Country
- 7.4.1. UK
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Russia
- 7.4.7. Rest of Europe
8. Asia Pacific Pharmaceutical Contract Manufacturing Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Service
- 8.2.1. Packaging
- 8.2.2. Drug Dose Formulation
- 8.2.3. Active Pharmaceutical Ingredient (API)
- 8.3. Market Analysis, Insights and Forecast – By Technology
- 8.3.1. Low-Tech Manufactures
- 8.3.2. High-Tech Manufactures
- 8.4. Market Analysis, Insights and Forecast – By Country
- 8.4.1. China
- 8.4.2. India
- 8.4.3. Japan
- 8.4.4. Australia
- 8.4.5. South East Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Pharmaceutical Contract Manufacturing Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Service
- 9.2.1. Packaging
- 9.2.2. Drug Dose Formulation
- 9.2.3. Active Pharmaceutical Ingredient (API)
- 9.3. Market Analysis, Insights and Forecast – By Technology
- 9.3.1. Low-Tech Manufactures
- 9.3.2. High-Tech Manufactures
- 9.4. Market Analysis, Insights and Forecast – By Country
- 9.4.1. Brazil
- 9.4.2. Saudi Arabia
- 9.4.3. UAE
- 9.4.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Althea Technologies
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Aenova
- 10.6. Dishman Pharmaceuticals and Chemicals Limited
- 10.7. Catalent Pharma Solutions
- 10.8. HAUPT Pharma AG
- 10.9. Famar
- 10.10. Kemwell Pvt. Ltd.
- 10.11. Jubilant Life Sciences Limited
- 10.12. Nipro Corp.
- 10.13. NextPharma
- 10.14. Recipharm
- 10.15. Pfizer Central Source
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
